Discovery of a 4-Azetidinyl-1-thiazoyl-cyclohexane CCR2 Antagonist as a Development Candidate

Xuqing Zhang,* Cuifen Hou, Heather Hufnagel, Monica Singer, Evan Opas, Sandra McKenney, Dana Johnson, and Zhihua Sui

Janssen Research and Development, LLC, Welsh & McKean Roads, Box 776, Spring House, Pennsylvania 19477, United States

Ⓢ *Supporting Information*

ABSTRACT: We have discovered a novel series of 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists. Divergent SAR studies on hCCR2 and hERG activities led to the discovery of compound **8d**, which displayed good hCCR2 binding affinity (IC$_{50}$, 37 nM) and potent functional antagonism (chemotaxis IC$_{50}$, 30 nM). It presented an IC$_{50}$ of >50 μM in inhibition of the hERG channel and had no effect on the QTc interval up to 10 mg/kg (i.v.) in anesthetized guinea pig and dog CV studies. It also displayed high selectivity over other chemokine receptors and GPCRs, and amendable oral bioavailability in dogs and primates. In a thioglycollate-induced inflammation model in hCCR2KI mice, it had ED$_{50}$ of 3 mg/kg on inhibition of the influx of leukocytes, monocytes/macrophages, and T-lymphocytes.

hCCR2 binding: 37 nM
hERG binding: > 50 μM
GPCV: no effect
TG: ED$_{50}$ = 3 mg/kg

8d

KEYWORDS: *Azetidine, CCR2, hERG, cardiovascular (CV) safety*

Monocyte chemotactic protein-1 (MCP-1) is one of the primary molecules controlling the influx of mononuclear leukocytes into sites of inflammation.[1,2] MCP-1 is a potent chemotactic factor for monocytes and memory T lymphocytes, and it stimulates the movement of those cells along a chemotactic gradient following binding to its cell-surface receptor, CC chemokine receptor-2 (CCR2). This ligand/receptor pair is overexpressed under numerous inflammatory conditions wherein excessive monocyte recruitment is observed. Indeed, CCR2- and MCP-1-deficient mice and CCR2 or MCP-1 antibody-treated rodents show decreased recruitment of monocytes and produce markedly attenuated inflammatory responses in animal models of rheumatoid arthritis (RAs),[3] multiple sclerosis,[4] asthma,[5] atherosclerosis,[6] diabetes,[7] allograft rejection,[8] and neuropathic pain.[9] Clearly, these observations confirm the role of CCR2 in the pathogenesis of several immune-based inflammatory diseases and identify this chemokine receptor as a potentially valuable therapeutic target. Thus, an antagonist of the binding of MCP-1 to its receptor may be an effective treatment for any inflammatory disease in which monocytes, mast cells, or basophils play major roles.

While a leading CCR2 antagonist MK-0812 failed to show significant improvement on RAs in clinical trials, there has been continuously intensive research interest in many distinct chemical series as CCR2 antagonists for other indications.[10−17] We have recently reported a novel series of 4-azetidinyl-1-arylcyclohexanes as CCR2 antagonists.[16] This scaffold is characterized by a general hERG liable structure consisting of a central basic amine flanked by two hydrophobes at the ends. Divergent SARs on hCCR2 and hERG activities enabled us to dial out hERG affinity and generated highly selective hCCR2 antagonists in the scaffold. The lead

compound **1** (Figure 1) possessed good hCCR2 binding affinity (IC$_{50}$, 15 nM), potent functional activity (chemotaxis,


hCCR2 binding: IC$_{50}$, 15 nM
hERG binding: IC$_{50}$, 25 μM

1

hCCR2 binding: IC$_{50}$, 190 nM
hERG binding: IC$_{50}$, 35 μM

2a

Figure 1. Early leads.

IC$_{50}$, 22 nM), and amendable separation over hERG activities. Disappointingly, i.v. treatment of anesthetized guinea pigs with **1** resulted in a significant dose dependent prolongation of the QTc interval (ΔQTc). At a dose of 10 mg/kg, a +20% ΔQTc was observed, with a drug plasma level of 12 μM being attained. Thus, **1** was abandoned from further development due to its unacceptable CV safety profile. Since QTc prolongation has been linked to preferential blockade of the voltage-gated potassium (K$^+$) channel encoded by the hERG, optimization of a structural series for lack of in vitro hERG affinity appears to be generally predictive of decreased potential to cause QTc prolongation in vivo. Herein, we report our continuous SAR

Table 1. SAR of Nitrogen Containing Six Membered Heterocyclic Analogues

ID	Het	hCCR2 binding IC$_{50}$ (nM)[a]	CTX IC$_{50}$ (nM)[b]	hERG IC$_{50}$ (μM)[c]	Patch Clamp %@3 μM (control)[d]
2a		190	nt[e]	35.0	28±7
2b		650	nt	43.8	19±7
2c	F	190	nt	10.0	54±4
2d	NC	170	nt	12.5	61±6
2e	Me	45	74	35.0	12±6
2f	MeO	44	56	37.0	29±3
2g	Me$_2$N	310	nt	22.5	61±10
2h	Me, MeO	220	nt	21.6	55±5
2i	MeO	71	nt	17.5	43±3
2j	MeO	250	nt	25.0	30±3
2k	EtO	18	30	14.5	68±2
2l	F$_3$CH$_2$CO	19	33	7.0	nt
2m	i-Pr-O	50	44	11.2	49±9
2n	t-Bu-O	49	17	5.5	nt
2o		27	43	9.8	nt

[a]MCP-1 receptor binding assay in THP-1 cells: for IC$_{50}$ > 100 nM (n = 1); for IC$_{50}$ < 100 nM (n > 2, average values, SEM < ±25%). [b]MCP-1 induced chemotaxis in THP-1 cells. [c]hERG ^{3}H-astemizole binding activity on the HEK-293 cell. [d]The membrane K$^+$ current IKr in hERG-transfected HEK293 cells (n = 3). [e]nt: not tested.

studies on identifying potent and selective hCCR2 antagonists devoid of this ancillary cardiac activity. Owing to the correlation between the ΔQTc observed with **1** in guinea pigs and the potency of **1** in the hERG binding assay, we defined hERG IC$_{50}$'s > 25 μM must be achieved to address the QTc issue. As a critical follow-up, a hERG patch clamp assay was used as a second front-line screening for eliminating compounds that displayed significant blockade of the potassium current, which is another *in vitro* indicator for causing QTc prolongation.

In the discovery of lead compound **1**, it was established that the cyclohexyl azetidine core as well as the right-end bis-amide functionality were critical for hCCR2 activity and might be too sensitive for modifications.[16] The left-end phenyl ring was somehow tolerated for moderate to good hCCR2 activity. For

this reason, we focused further optimization on the left-end aromatic group. Replacement of the phenyl group at the 1-position of the cyclohexyl ring with the 3-pyridinyl group resulted in a significant loss of hCCR2 activity but also further attenuated hERG binding affinity (**2a**: hCCR2 IC$_{50}$, 190 nM; hERG IC$_{50}$, 35 μM).[15–17] These data prompted us to take nitrogen containing six membered aromatic rings as the starting point for subsequent optimization (Table 1). Compound **2b**, bearing a more polar pyrimidinyl group, displayed even weaker hCCR2 binding affinity (IC$_{50}$, 650 nM) compared with **2a**. We then examined the substituent effect on both hCCR2 and hERG inhibition among the pyridinyl derivatives. Electron withdrawing groups such as fluoro or cyano did not improve hCCR2 binding, as indicated with **2c** and **2d**, with IC$_{50}$ values

of 190 nM and 170 nM, respectively. In contrast, the electron donating group, exemplified by methoxy and methyl groups, had a beneficial effect on hCCR2 activity, as evidenced by an approximate 3−5-fold increase of binding affinity (**2e** and **2f** vs **2a**). The improved potency of **2e** and **2f** was also translated into good levels of activity in the chemotaxis assay with IC_{50} values of 74 nM and 56 nM, respectively. To our delight, installation of both substituents maintained good selectivity between hCCR2 and hERG binding affinities (hERG binding IC_{50} of 35 and 37 μM). The weak hERG affinities of both compounds were further confirmed with only 12% and 29% of inhibition at 3 μM in the patch clamp assay. The dimethylamino analogue **2g** was ~8-fold weaker for hCCR2 binding than **2f**. Addition of a methyl group *ortho* to the methoxy group also resulted in significant loss of hCCR2 affinity, as shown by **2h** (IC_{50}, 220 nM). The two methoxy-pyridinyl regioisomers **2i** and **2j** displayed weaker hCCR2 binding affinities (IC_{50}, 71 and 250 nM) compared with that of **2f**, indicating that the electronic density of the pyridinyl ring had a great impact on the hCCR2 activity. As expected, installation of more lipophilic 4-alkoxy groups maintained or improved both hCCR2 binding affinity and chemotaxis activity, as illustrated by **2k**−**2o**. Steric bulkiness on the alkoxy group was well tolerated for good hCCR2 activity (**2m, 2n, 2o**). Unfortunately, the unwanted hERG signals among these derivatives reappeared to be problematic for further evaluations.

Given the good *in vitro* selectivity between hCCR2 and hERG activities, **2e** and **2f** were selected for evaluation in an anesthetized guinea pig CV (GPCV) study. Disappointingly, both **2e** and **2f** still displayed electrocardiographic effects consisting of a dose dependent increase in ΔQTc. With a dosage of 10 mg/kg (i.v.), **2e** and **2f** exhibited +13% and +6% of the ΔQTc, respectively. These results led us to redefine our criteria on the *in vitro* hERG profile for advancing compounds into the GPCV study. Our efforts then focused on identifying compounds with decreased hERG affinity to our detection limit (IC_{50}, 50 μM) while maintaining or improving hCCR2 activities. However, an attempt on determining the direct correlation between hERG binding and QTc prolongation could be challenging due to the impact on QTc from other factors, for example, serum protein binding. Therefore, the final selection of the compounds for further development should be solely determined by comprehensive *in vivo* CV safety evaluation.

Reviewing the recent literature led us to postulate that the weak basic pyridinyl group of **2e** and **2f** may participate in a cation−π interaction with the Tyr-652 residue of the hERG channel.[18] Thus, elimination of the basic feature of the pyridinyl group would disrupt this interaction and further attenuate hERG binding. For the chemistry effort, we decided to examine the left-end aromatic ring with a series of five membered heterocyclic analogues. As illustrated in Table 2, substitution by a five membered heterocycle had a great impact on hCCR2 affinity. While incorporation of an oxazole (**3**), imidazole (**4**), pyrrozole (**5**), or thiadiazole (**6**) either efficiently attenuated or abolished hERG affinity, it also significantly reduced hCCR2 activity. To our satisfaction, installation of a 2-thiophene (**7**), 2-thiazole (**8a**), or 2-isothiazole (**9**) at the 1-postion of the cyclohexyl ring was tolerated for good hCCR2 binding affinity (IC_{50}, 100, 62, 36 nM). Among them, **8a** displayed relatively weak hERG binding affinity with an IC_{50} of 32 μM and promising separation between hCCR2 and hERG

**Table 2. SAR of Five Membered Heterocyclic Analogues**

ID	(Het)	hCCR2 Binding IC_{50} (nM)	hERG Binding IC_{50} (μM)
3		2,820	> 50
4		5,300	15.0
5		2,700	> 50
6		790	> 50
7		100	27.0
8a		62	32.0
9		36	24.0

affinities, which prompted us to investigate this substitution pattern in detail.

Table 3 highlighted the SAR within a series of thiazole substituted analogues. Installation of a thiazole moiety at the 1-position of the cyclohexyl ring was generally well tolerated for good hCCR2 activity. However, modification on the thiazole group had a great impact on the *in vitro* hERG profile and, hence, dominated the QTc effect in the GPCV study. There was a trend that more lipophilic thiazoles led to stronger hERG *in vitro* activity. Compared to **8a**, simple methylation at the 3-position of the thiazole caused the blockade of hERG potassium current from 35% to 49% at 3 μM (**8b**). It is therefore not surprising that intravenous infusion of **8b** in anesthetized guinea pigs triggered a dose dependent QTc prolongation (ΔQTc, +15% at 10 mg/kg). Compound **8c**, bearing a hydrophobic benzothiazole moiety, possessed enhanced hERG *in vitro* activity. Installation of a 5-thaizole group onto the 1-position of the cyclohexyl ring (**8d**) remarkably attenuated the hERG binding affinity to greater than 50 μM. Consistent with its weak hERG affinity, **8d** also displayed low inhibition on the potassium current in the patch clamp study (21% inhibition at 3 μM). To our delight, intravenous infusion of **8d** in anesthetized guinea pigs had no effect on QTc up to 10 mg/kg. The plasma concentration reached 26 μM. Having identified the 5-thiazole group as the preferred left-end moiety, we extended our SAR studies to several substituted 5-thiazole analogues. Compounds **8e** and **8f**, with small alkyl substitutions, displayed good hCCR2 activities and the desired *in vitro* hERG profile. Furthermore, **8f** demonstrated no effect on QTc up to 10 mg/kg (i.v.) in the GPCV study (plasma level, 10 μM). It is noteworthy that the 5-thiazole is not considered as a general pharmacophore for suppressing hERG *in vitro* activities and eliminating QTc prolongation in the GPCV study. As illustrated by **8g** and **8h**, while maintaining good hCCR2 activities, they both possessed

Table 3. SAR of Thiazole Substituted Analogues

ID	Ar	hCCR2 binding IC$_{50}$ (nM)	CTX IC$_{50}$ (nM)	hERG Binding IC$_{50}$ (μM)	Patch Clamp % @ 3 μM (control)	GPCV ΔQTc@10 mg/kg (+%)[a]
8a		62	13	32	30±4	nt
8b		18	60	28	49±3	+15
8c		16	28	6.2	80±9	nt
8d		37	30	> 50	21±1	no effect
8e		78	65	> 50	21±5	nt
8f		57	70	> 50	35±3	no effect
8g		5	4	28	49±6	no effect
8h		41	68	6.0	77±5	nt

[a]Cumulative doses (0.1, 0.3, 1, 3, and 10 mg/kg) were administered incrementally as 5 min i.v. infusions at 0, 20, 40, 60, and 80 min. QTc intervals (ΔQTc) were measured and recorded at each time point as a percent change from baseline for each animal. Values are mean ± SEM ($n = 3$).

Scheme 1. Synthesis of 8d[a]

[a]Conditions: (a) n-BuLi, −78 °C. (b) TBAF, 2 steps, 55%. (c) HCl, acetone, room temperature, 90%. (d) NaBH(OAc)$_3$, TEA, DCM, room temperature, 35% along with its isomer, 40%.

enhanced inhibition on the potassium current (49% and 77% inhibition at 3 μM). While compound **8g** displayed no effect on QTc up to 10 mg/kg (i.v.) in the GPCV study, the plasma concentration was only ~3 μM which did not provide enough safety margin for further development. Here, an extremely narrow line appeared to determine the CV safety profile of this series.

Given its superior *in vitro* hERG and GPCV safety profiles, **8d** was selected to be further evaluated in an anesthetized dog CV safety study. Strikingly, it did not induce dose-dependent or notable effects on most cardiohemodynamic, functional respiratory, and electrophysiological parameters up to 10 mg/kg (i.v.) with the plasma level at 70 μM. It also did not induce

changes in ECG morphology. Overall, **8d** represented the first compound with a good CV safety profile as a development candidate.

Compound **8d** was a selective hCCR2 inhibitor, showing no significant inhibitory activity at the concentration of 10 μM in Cerep and Invitrogen protein kinase panel screens. It did not significantly inhibit the binding of any of the relevant chemokines tested, including CCR1, CCR3, CCR4, CCR5, CXCR1, CXCR2, CXCR4, and CX3CR1 at the concentration of 25 μM.

Compound **8d** also exhibited amendable DMPK profiles for further development. It was highly orally bioavailable and exhibited oral bioavailability of 70.2% in dogs when dosed at 6.7

1042

dx.doi.org/10.1021/ml300260s | ACS Med. Chem. Lett. 2012, 3, 1039−1044

mg/kg using 0.5% methocel as a vehicle (C_{max} = 1617 ng/mL, AUC_{last} = 5887 h·ng/mL). In addition, it showed 25.4% oral bioavailability in nonhuman primates (7.2 mg/kg p.o., C_{max} = 740 ng/mL, AUC_{last} = 3061 h·ng/mL) but only 19% of oral bioavailability in mice (10 mg/kg p.o., C_{max} = 74 ng/mL, AUC_{last} = 204 h·ng/mL), and 15.3% oral bioavailability in rats (10 mg/kg p.o., C_{max} = 100 ng/mL, AUC_{last} = 416 h·ng/mL).

Compound **8d** only displayed a K_i of 9.6 μM for mCCR2 binding. Human CCR2 knock-in/murine CCR2 knockout mice (hCCR2KI) have been adopted to overcome the species issue and validate in vivo models. Compound **8d** was assessed in several pharmacological models using hCCR2KI mice. In a thioglycollate-induced peritonitis (TG) model, it dose-dependently inhibited the influx of leukocytes, monocytes/macrophages, and T-lymphocytes into the peritoneal cavity with an ED_{50} of 3 mg/kg p.o. bid. In an OVA-induced asthma model, **8d** inhibited airway eosinophil infiltration by 89% at a dose of 10 mg/kg p.o. bid. The efficacy of **8d** in the mouse model suggests that it may have potential as a single agent in asthma to improve signs and symptoms and reduce airway resistance. The detailed pharmacological profile of **8d** will be reported later.

The synthesis of this series is exemplified by compound **8d**, as illustrated in Scheme 1. Thiazole **10** was treated with n-BuLi in THF at −78 °C, and the resulting anion was reacted with commercially available ketone **11** followed by desilylation with TBAF to obtain ketal **12** in 55% yield. Deprotection of the ketal group in 1 N HCl/acetone at room temperature gave the corresponding ketone **13** in 90% yield. Reductive amination of **13** with **14**[16] using NaBH(OAc)$_3$ gave a pair of *cis*−*trans* adducts as mixtures, which were separated by silica gel column chromatography to afford *cis* isomer (in terms of thiazole and azetidine moiety) **8d** in 35% yield along with its *trans* isomer (structure not shown) in 40% yield.

In conclusion, we have discovered a novel series of azetidinyl cyclohexanes as potent and selective hCCR2 antagonists. Through divergent SARs of hCCR2 and hERG on the left-end heterocyclic ring, **8d** was identified as the lead compound. It exhibits potent hCCR2 activity, high selectivity, weak hERG affinity, and good oral bioavailability. Evaluated in guinea pigs and dogs, **8d** possesses a clean CV safety profile and provides a good safety margin as a development candidate.

ASSOCIATED CONTENT

Ⓢ Supporting Information

Experimental procedures for the synthesis of **8d** and characterization data for **2a−2o**, **3−7**, **8a−h**, and **9**, as well as in vitro and in vivo biological protocols. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

*Tel: 215-628-7877. Fax: 215-540-4612. E-mail: xzhang5@its.jnj.com.

Notes

The authors declare no competing financial interest..

ACKNOWLEDGMENTS

REFERENCES

(1) Charo, I. F.; Ransohoff, R. M. The many roles of chemokines and chemokine receptors in inflammation. *N. Engl. J. Med.* **2006**, *354*, 610−621.

(2) Castellani, M. L.; Bhattacharya, K.; Tagen, M.; Kempuraj, D.; Perrella, A.; Delutis, M.; Boucher, W.; Conti, P.; Theoharides, T. C.; Cerulli, G.; Salini, V.; Neri, G. Anti-chemokine therapy for inflammatory diseases. *Int. J. Immunopathol. Pharmacol.* **2007**, *20*, 447−453.

(3) Ogata, H.; Takeya, M.; Yoshimura, T.; Takagi, K.; Takahashi, K. The role of monocyte chemoattractant protein-1 (MCP-1) in the pathogenesis of collagen-induced arthritis in rats. *J. Pathol.* **1997**, *182*, 106−114.

(4) Fife, B. T.; Huffnagle, G. B.; Kuziel, W. A.; Karpus, W. J. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. *J. Exp. Med.* **2000**, *192*, 899−905.

(5) Kim, Y. K.; OH, H. B.; Lee, E. Y.; Lee, J. E.; Kim, Y. Y. Association between a genetic variation of CC chemokine receptor 2 and atopic asthma. *Allergy* **2007**, *62*, 207−208.

(6) Dawson, T. C.; Kuziel, W. A.; Osahar, T. A.; Maeda, N. Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. *Atherosclerosis* **1999**, *143*, 205−211.

(7) Kanda, H.; Tateya, S.; Tamori, Y.; Kotani, K.; Hiasa, K. I.; Kitazawa, R.; Kitazawa, S.; Miyachi, H.; Maeda, S.; Egashira, K.; Kasuga, M. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. *J. Clin. Invest.* **2006**, *116*, 1494−1505.

(8) Abdi, R.; Means, T. K.; Ito, T.; Smith, R. N.; Najafian, N.; Jurewicz, M.; Tchipachvili, V.; Charo, I.; Auchincloss, H., Jr.; Sayegh, M. H.; Luster, A. D. Differential role of CCR2 in islet and heart allograft rejection: tissue specificity of chemokine/chemokine receptor function in vivo. *J. Immunol.* **2004**, *172*, 767−775.

(9) White, F. A.; Feldman, P.; Miller, R. J. Chemokine signaling neuropathic pain. *Mol. Interventions* **2009**, *9*, 188−195.

(10) Struthers, M.; Pasternak, A. CCR2 antagonists. *Curr. Top. Med. Chem.* **2010**, *10*, 1278−1298.

(11) Hou, C.; Sui, Z. CCR2 antagonists for the treatment of diseases associated with inflammation" Anti-inflammatory drug discovery; Levin, J., Laufer, S., Eds.; Royal Society of Chemistry, 2012; pp 350−390.

(12) Xue, C.-B.; Wang, A.; Meloni, D.; Zhang, K.; Kong, L.; Feng, H.; Glenn, J.; Huang, T.; Zhang, Y.; Cao, G.; Anand, R.; Zheng, C.; Xia, M.; Han, Q.; Robinson, D. J.; Storace, L.; Shao, L.; Li, M.; Brodmerkel, C. M.; Covington, M.; Scherle, P.; Diamond, S.; Yeleswaram, S.; Vaddi, K.; Newton, R.; Hollis, G.; Friedman, S.; Metcalf, B. Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 7473−7478.

(13) Xue, C.-B.; Feng, H.; Cao, G.; Huang, T.; Glenn, J.; Anand, R.; Meloni, D.; Zhang, K.; Kong, L.; Wang, A.; Zhang, Y.; Zheng, C.; Xia, M.; Chen, L.; Tanaka, H.; Han, Q.; Robinson, D. J.; Modi, D.; Storace, L.; Shao, L.; Sharief, V.; Li, M.; Galya, L. G.; Covington, M.; Scherle, P.; Diamond, S.; Emm, T.; Yeleswaram, S.; Contel, N.; Vaddi, K.; Newton, R.; Hollis, G.; Friedman, S.; Metcalf, B. Discovery of INCB3284, a potent, selective, and orally bioavailable hCCR2 antagonist. *ACS Med. Chem. Lett.* **2011**, *2*, 450−454.

(14) Xue, C.-B.; Wang, A.; Han, Q.; Zhang, Y.; Cao, G.; Feng, H.; Huang, T.; Zheng, C.; Xia, M.; Zhang, K.; Kong, L.; Glenn, J.; Anand, R.; Meloni, D.; Robinson, D. J.; Shao, L.; Storace, L.; Li, M.; Hughes, R. O.; Devraj, R.; Morton, P. A.; Rogier, D. J.; Covington, M.; Scherle, P.; Diamond, S.; Emm, T.; Yeleswaram, S.; Contel, N.; Vaddi, K.; Newton, R.; Hollis, G.; Metcalf, B. Discovery of INCB8761/PF-4136309, a potent, selective, and orally bioavailable CCR2 antagonist. *ACS Med. Chem. Lett.* **2011**, *2*, 913−918.

(15) Lanter, J. C.; Markotan, T. P.; Zhang, X.; Subasinghe, N.; Kang, F.-A.; Hou, C.; Singer, M.; Opas, E.; McKenney, S.; Crysler, C.; Johnson, D.; Molloy, C. J.; Sui, Z. The discovery of novel cyclohexylamide CCR2 antagonists. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 7496−7501.

1043

dx.doi.org/10.1021/ml300260s | *ACS Med. Chem. Lett.* 2012, 3, 1039−1044

(16) Zhang, X.; Hufnagel, H.; Markotan, T.; Lanter, J.; Cai, C.; Hou, C.; Singer, M.; Opas, E.; McKenney, S.; Crysler, C.; Johnson, D.; Sui, Z. Overcoming hERG activity in the discovery of a series of 4-azetidinyl-1-arylcyclohexanes as CCR2 antagonists. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 5577−5582.

(17) Zhang, X.; Hufnagel, H.; Hou, C.; Opas, E.; McKenney, S.; Crysler, C.; O'Neill, J.; Johnson, D.; Sui, Z. Design, synthesis and SAR of indazole and benzoisoxazole containing 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 6042−6048.

(18) Fernandez, D.; Ghanta, A.; Kauffman, G. W.; Sanguinetti, M. C. Physicochemical Features of the hERG Channel Drug Binding Site. *J. Biol. Chem.* **2004**, *279*, 10120−10127.